Towards tailored management of malignant brain tumors with nanotheranostics

Aparicio-Blanco, Juan; Torres-Suárez, Ana Isabel

doi:10.1016/j.actbio.2018.04.029

Cited by 17 publications

(14 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main advantages of inorganic NPS (mesoporous silica nanoparticles, gold nanoparticles, iron oxide nanoparticles, and quantum dots) are their resistance to enzymatic degradation, robustness, and interesting intrinsic characteristics (Nam et al, 2013). For the treatment of GB, different kind of NPS (lipidic, magnetic, liposomal, fluorescent, and polymeric) have already been designed in order to cross the BBB, and these take into account active, passive, and stimuli-targeting perspectives (Cheng et al, 2014; Saraiva et al, 2016; Miranda et al, 2017; Aparicio-Blanco and Torres-Suárez, 2018). Theranostic nanoparticles represent a new technological concept that provides a combination of inorganic and organic nanoparticles to acquire synergistic characteristics in a single nanoparticle, exploiting the drug delivery by organic NPS and imaging by inorganic NPS.…”

Section: Nanoparticles For Gb Treatmentmentioning

confidence: 99%

Theranostic Nanomedicine for Malignant Gliomas

d’Angelo

Castelli

Benedetti

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Brain tumors mainly originate from glial cells and are classified as gliomas. Malignant gliomas represent an incurable disease; indeed, after surgery and chemotherapy, recurrence appears within a few months, and mortality has remained high in the last decades. This is mainly due to the heterogeneity of malignant gliomas, indicating that a single therapy is not effective for all patients. In this regard, the advent of theranostic nanomedicine, a combination of imaging and therapeutic agents, represents a strategic tool for the management of malignant brain tumors, allowing for the detection of therapies that are specific to the single patient and avoiding overdosing the non-responders. Here, recent theranostic nanomedicine approaches for glioma therapy are described.

show abstract

Section: Nanoparticles For Gb Treatmentmentioning

confidence: 99%

Theranostic Nanomedicine for Malignant Gliomas

d’Angelo

Castelli

Benedetti

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Malignant brain tumors are more common and are approximated to outnumber primary brain tumors by a factor of four 4 . Metastasis to the brain occurs in approximately 10% to 30% of cancer patients with 70% to 80% of those individuals developing multiple lesions, most commonly in the cerebrum 5 , 6 .…”

Section: Brain Cancer Epidemiologymentioning

confidence: 99%

Effects of Lovastatin on Brain Cancer Cells

et al. 2022

View full text Add to dashboard Cite

Although brain tumors occur less frequently than other forms of cancer, they have one of the bleakest prognoses with low survival rates. The conventional treatment for brain tumors includes surgery, radiotherapy, and chemotherapy. However, resistance to treatment remains a problem with recurrence shortly following. The resistance to treatment may be caused by cancer stem cells (CSCs), a subset of brain tumor cells with the affinity for self-renewal and differentiation into multiple cell lineages. An emerging approach to targeting CSCs in brain tumors is through repurposing the lipid-lowering medication, lovastatin. Lovastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that impacts the mevalonate pathway. The inhibition of intermediates in the mevalonate pathway affects signaling cascades and oncogenes associated with brain tumor stem cells (BTSC). In this review, we show the possible mechanisms where lovastatin can target BTSC for different varieties of malignant brain tumors.

show abstract

“…As such, many treatment protocols for different diseases have evolved greatly due to the growing ascension of this specific area [97][98][99]. According to works from the literature, a unique capability of nanoteranostics is the possibility of eliminating malignant tumors and their respective metastases via methods that are less invasive and have higher subcellular precision, which is a characteristic defined by the size of the action zone of the nanoparticles in use [100][101][102].…”

Section: Nanomaterialsmentioning

confidence: 99%

Designing of Nanomaterials-Based Enzymatic Biosensors: Synthesis, Properties, and Applications

et al. 2021

View full text Add to dashboard Cite

Among the many biological entities employed in the development of biosensors, enzymes have attracted the most attention. Nanotechnology has been fostering excellent prospects in the development of enzymatic biosensors, since enzyme immobilization onto conductive nanostructures can improve characteristics that are crucial in biosensor transduction, such as surface-to-volume ratio, signal response, selectivity, sensitivity, conductivity, and biocatalytic activity, among others. These and other advantages of nanomaterial-based enzymatic biosensors are discussed in this work via the compilation of several reports on their applications in different industrial segments. To provide detailed insights into the state of the art of this technology, all the relevant concepts around the topic are discussed, including the properties of enzymes, the mechanisms involved in their immobilization, and the application of different enzyme-derived biosensors and nanomaterials. Finally, there is a discussion around the pressing challenges in this technology, which will be useful for guiding the development of future research in the area.

show abstract

Towards tailored management of malignant brain tumors with nanotheranostics

Cited by 17 publications

References 112 publications

Theranostic Nanomedicine for Malignant Gliomas

Theranostic Nanomedicine for Malignant Gliomas

Effects of Lovastatin on Brain Cancer Cells

Designing of Nanomaterials-Based Enzymatic Biosensors: Synthesis, Properties, and Applications

Contact Info

Product

Resources

About